Shearman & Sterling represented BofA Securities, Inc., Morgan Stanley & Co. LLC, Citigroup Global Markets Inc. and Goldman Sachs & Co. LLC as joint book-running managers and representatives of the underwriters in connection with Amgen Inc.’s registered $4 billion notes offering, consisting of $750 million 3.000% senior notes due 2029, $1 billion 3.350% senior notes due 2032, $1 billion 4.200% senior notes due 2052 and $1.25 billion 4.400% senior notes due 2062. The 3.000% senior notes due 2029 were Amgen’s inaugural offering of “green bonds,” the proceeds of which will be used for Amgen’s eligible green projects.

Amgen Inc. is a global biotechnology company that discovers, develops, manufactures and delivers human therapeutics based on advances in cellular and molecular biology.

The Shearman & Sterling team below included associates Anna Nagornaia, Margeaux Bergman (both Menlo Park-Capital Markets) and Christina Myrold (San Francisco – Litigation).

The Team